- Home
- INTS vs XAIR Comparison
INTS vs XAIR Comparison
Compare INTS & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- XAIR
- Stock Information
- Founded
- INTS 2012
- XAIR 2011
- Country
- INTS United States
- XAIR United States
- Employees
- INTS N/A
- XAIR N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- INTS Health Care
- XAIR Health Care
- Exchange
- INTS Nasdaq
- XAIR Nasdaq
- Market Cap
- INTS 12.2M
- XAIR 10.5M
- IPO Year
- INTS 2023
- XAIR N/A
- Fundamental
- Price
- INTS $0.42
- XAIR $1.29
- Analyst Decision
- INTS Strong Buy
- XAIR Strong Buy
- Analyst Count
- INTS 4
- XAIR 1
- Target Price
- INTS $4.50
- XAIR $11.00
- AVG Volume (30 Days)
- INTS 87.5M
- XAIR 1.2M
- Earning Date
- INTS 11-06-2025
- XAIR 11-10-2025
- Dividend Yield
- INTS N/A
- XAIR N/A
- EPS Growth
- INTS N/A
- XAIR N/A
- EPS
- INTS N/A
- XAIR N/A
- Revenue
- INTS N/A
- XAIR $5,802,000.00
- Revenue This Year
- INTS N/A
- XAIR $261.11
- Revenue Next Year
- INTS N/A
- XAIR $151.82
- P/E Ratio
- INTS N/A
- XAIR N/A
- Revenue Growth
- INTS N/A
- XAIR 147.74
- 52 Week Low
- INTS $0.19
- XAIR $1.19
- 52 Week High
- INTS $3.18
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- INTS 50.05
- XAIR 27.60
- Support Level
- INTS $0.38
- XAIR $1.19
- Resistance Level
- INTS $0.50
- XAIR $1.53
- Average True Range (ATR)
- INTS 0.07
- XAIR 0.14
- MACD
- INTS -0.02
- XAIR -0.02
- Stochastic Oscillator
- INTS 18.75
- XAIR 11.36
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.